Indication
Non Small Cell Lung Carcinoma
2 clinical trials
10 products
Clinical trial
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC).Status: Active (not recruiting), Estimated PCD: 2020-09-21
Product
Durvalumab + TremelimumabProduct
Paclitaxel + CarboplatinProduct
Gemcitabine + cisplatinProduct
Gemcitabine + CarboplatinProduct
Pemetrexed + CisplatinProduct
Pemetrexed + CarboplatinProduct
Durvalumab +TremelimumabProduct
Gemcitabine + CisplatinProduct
Pemetrexed + cisplatinClinical trial
A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of Care (SoC) Platinum-Based Chemotherapy as First Line Treatment in Patients With PD-L1-High Expression Advanced Non Small-Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2022-10-27
Product
Durvalumab